Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Allarity Therapeutics Inc. (ALLR) Insider Trading Activity
Healthcare • Biotechnology • 5 employees
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Total Value
$249,999.13
Total Shares
689,154
Average Trade Value
$62,499.78
Most Active Insider
Graff Jeremy R.
Total Activity: $249,999
Largest Single Transaction
$249,999
by Graff Jeremy R. on Sep 30, 2024
30-Day Activity
0 Transactions
Volume: 0 shares
Value: $0
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
CFO
Officer
|
Jan 22, 2025 | 29,496 | $0 | 85,051 (+34.7%) | Grant | |
|
Cdo
Officer
|
Jan 22, 2025 | 144,441 | $0 | 262,924 (+54.9%) | Grant | |
|
CEO
Officer
|
Jan 22, 2025 | 396,734 | $0 | 396,734 (+100.0%) | Grant | |
|
See Remarks
Officer
|
Sep 30, 2024 | 118,483 | $249,999 | 118,483 (+100.0%) | Grant |